201 related articles for article (PubMed ID: 22689920)
1. BCL2 suppresses PARP1 function and nonapoptotic cell death.
Dutta C; Day T; Kopp N; van Bodegom D; Davids MS; Ryan J; Bird L; Kommajosyula N; Weigert O; Yoda A; Fung H; Brown JR; Shapiro GI; Letai A; Weinstock DM
Cancer Res; 2012 Aug; 72(16):4193-203. PubMed ID: 22689920
[TBL] [Abstract][Full Text] [Related]
2. Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737.
Del Gaizo Moore V; Brown JR; Certo M; Love TM; Novina CD; Letai A
J Clin Invest; 2007 Jan; 117(1):112-21. PubMed ID: 17200714
[TBL] [Abstract][Full Text] [Related]
3. The BH3-only mimetic ABT-737 synergizes the antineoplastic activity of proteasome inhibitors in lymphoid malignancies.
Paoluzzi L; Gonen M; Bhagat G; Furman RR; Gardner JR; Scotto L; Gueorguiev VD; Heaney ML; Manova K; O'Connor OA
Blood; 2008 Oct; 112(7):2906-16. PubMed ID: 18591385
[TBL] [Abstract][Full Text] [Related]
4. γ-Secretase inhibition promotes cell death, Noxa upregulation, and sensitization to BH3 mimetic ABT-737 in human breast cancer cells.
Séveno C; Loussouarn D; Bréchet S; Campone M; Juin P; Barillé-Nion S
Breast Cancer Res; 2012 Jun; 14(3):R96. PubMed ID: 22703841
[TBL] [Abstract][Full Text] [Related]
5. The putative BH3 mimetic S1 sensitizes leukemia to ABT-737 by increasing reactive oxygen species, inducing endoplasmic reticulum stress, and upregulating the BH3-only protein NOXA.
Soderquist R; Pletnev AA; Danilov AV; Eastman A
Apoptosis; 2014 Jan; 19(1):201-9. PubMed ID: 24072590
[TBL] [Abstract][Full Text] [Related]
6. Selective targeting of BCL6 induces oncogene addiction switching to BCL2 in B-cell lymphoma.
Dupont T; Yang SN; Patel J; Hatzi K; Malik A; Tam W; Martin P; Leonard J; Melnick A; Cerchietti L
Oncotarget; 2016 Jan; 7(3):3520-32. PubMed ID: 26657288
[TBL] [Abstract][Full Text] [Related]
7. Functional inhibition of BCL2 is needed to increase the susceptibility to apoptosis to SMO inhibitors in diffuse large B-cell lymphoma of germinal center subtype.
Kunkalla K; Liu Y; Qu C; Leventaki V; Agarwal NK; Singh RR; Vega F
Ann Hematol; 2013 Jun; 92(6):777-87. PubMed ID: 23370596
[TBL] [Abstract][Full Text] [Related]
8. Cap-translation inhibitor, 4EGI-1, restores sensitivity to ABT-737 apoptosis through cap-dependent and -independent mechanisms in chronic lymphocytic leukemia.
Willimott S; Beck D; Ahearne MJ; Adams VC; Wagner SD
Clin Cancer Res; 2013 Jun; 19(12):3212-23. PubMed ID: 23633452
[TBL] [Abstract][Full Text] [Related]
9. Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1.
Yecies D; Carlson NE; Deng J; Letai A
Blood; 2010 Apr; 115(16):3304-13. PubMed ID: 20197552
[TBL] [Abstract][Full Text] [Related]
10. MEK inhibition enhances ABT-737-induced leukemia cell apoptosis via prevention of ERK-activated MCL-1 induction and modulation of MCL-1/BIM complex.
Konopleva M; Milella M; Ruvolo P; Watts JC; Ricciardi MR; Korchin B; McQueen T; Bornmann W; Tsao T; Bergamo P; Mak DH; Chen W; McCubrey J; Tafuri A; Andreeff M
Leukemia; 2012 Apr; 26(4):778-87. PubMed ID: 22064351
[TBL] [Abstract][Full Text] [Related]
11. A novel paradigm for rapid ABT-737-induced apoptosis involving outer mitochondrial membrane rupture in primary leukemia and lymphoma cells.
Vogler M; Dinsdale D; Sun XM; Young KW; Butterworth M; Nicotera P; Dyer MJ; Cohen GM
Cell Death Differ; 2008 May; 15(5):820-30. PubMed ID: 18309326
[TBL] [Abstract][Full Text] [Related]
12. Gossypol overcomes stroma-mediated resistance to the BCL2 inhibitor ABT-737 in chronic lymphocytic leukemia cells ex vivo.
Soderquist R; Bates DJ; Danilov AV; Eastman A
Leukemia; 2013 Nov; 27(11):2262-4. PubMed ID: 23640104
[No Abstract] [Full Text] [Related]
13. Cytotoxicity, drug combinability, and biological correlates of ABT-737 against acute lymphoblastic leukemia cells with MLL rearrangement.
Jayanthan A; Incoronato A; Singh A; Blackmore C; Bernoux D; Lewis V; Stam R; Whitlock JA; Narendran A
Pediatr Blood Cancer; 2011 Mar; 56(3):353-60. PubMed ID: 21225911
[TBL] [Abstract][Full Text] [Related]
14. BH3 mimetics suppress CXCL12 expression in human malignant peripheral nerve sheath tumor cells.
Graham CD; Kaza N; Pruitt HC; Gibson LM; Klocke BJ; Shevde LA; Carroll SL; Roth KA
Oncotarget; 2017 Jan; 8(5):8670-8678. PubMed ID: 28055968
[TBL] [Abstract][Full Text] [Related]
15. Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors.
Du Y; Yamaguchi H; Wei Y; Hsu JL; Wang HL; Hsu YH; Lin WC; Yu WH; Leonard PG; Lee GR; Chen MK; Nakai K; Hsu MC; Chen CT; Sun Y; Wu Y; Chang WC; Huang WC; Liu CL; Chang YC; Chen CH; Park M; Jones P; Hortobagyi GN; Hung MC
Nat Med; 2016 Feb; 22(2):194-201. PubMed ID: 26779812
[TBL] [Abstract][Full Text] [Related]
16. ABT-737 resistance in B-cells isolated from chronic lymphocytic leukemia patients and leukemia cell lines is overcome by the pleiotropic kinase inhibitor quercetin through Mcl-1 down-regulation.
Russo M; Spagnuolo C; Volpe S; Tedesco I; Bilotto S; Russo GL
Biochem Pharmacol; 2013 Apr; 85(7):927-36. PubMed ID: 23353698
[TBL] [Abstract][Full Text] [Related]
17. BCL2/BCL-X(L) inhibition induces apoptosis, disrupts cellular calcium homeostasis, and prevents platelet activation.
Vogler M; Hamali HA; Sun XM; Bampton ET; Dinsdale D; Snowden RT; Dyer MJ; Goodall AH; Cohen GM
Blood; 2011 Jun; 117(26):7145-54. PubMed ID: 21562047
[TBL] [Abstract][Full Text] [Related]
18. The BH3 mimetic compound, ABT-737, synergizes with a range of cytotoxic chemotherapy agents in chronic lymphocytic leukemia.
Mason KD; Khaw SL; Rayeroux KC; Chew E; Lee EF; Fairlie WD; Grigg AP; Seymour JF; Szer J; Huang DC; Roberts AW
Leukemia; 2009 Nov; 23(11):2034-41. PubMed ID: 19641525
[TBL] [Abstract][Full Text] [Related]
19. Targeting of BCL2 Family Proteins with ABT-199 and Homoharringtonine Reveals BCL2- and MCL1-Dependent Subgroups of Diffuse Large B-Cell Lymphoma.
Klanova M; Andera L; Brazina J; Svadlenka J; Benesova S; Soukup J; Prukova D; Vejmelkova D; Jaksa R; Helman K; Vockova P; Lateckova L; Molinsky J; Maswabi BC; Alam M; Kodet R; Pytlik R; Trneny M; Klener P
Clin Cancer Res; 2016 Mar; 22(5):1138-49. PubMed ID: 26467384
[TBL] [Abstract][Full Text] [Related]
20. BAX and BAK1 are dispensable for ABT-737-induced dissociation of the BCL2-BECN1 complex and autophagy.
Pedro JM; Wei Y; Sica V; Maiuri MC; Zou Z; Kroemer G; Levine B
Autophagy; 2015; 11(3):452-9. PubMed ID: 25715028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
